趋化因子受体CXCR4在癌细胞中的表达意义。

The significance of cancer cell expression of the chemokine receptor CXCR4.

作者信息

Balkwill Fran

机构信息

Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London EC1M 6BQ, UK.

出版信息

Semin Cancer Biol. 2004 Jun;14(3):171-9. doi: 10.1016/j.semcancer.2003.10.003.

DOI:10.1016/j.semcancer.2003.10.003

PMID:15246052

Abstract

Malignant cells from at least 23 different types of cancer express the chemokine receptor CXCR4 and respond to its ligand CXCL12. This receptor ligand pair appears to be involved in directed migration of cancer cells to sites of metastasis, increased survival of cancer cells in sub optimal conditions and establishment of a tumour promoting cytokine/chemokine network. Preliminary data from animal models suggest that CXCR4 may be an important therapeutic target in a range of cancers. However CXCR4 plays major roles in embryogenesis, homeostasis and inflammation. This raises questions concerning the specificity of CXCR4 antagonists in the treatment of cancer.

摘要

来自至少23种不同类型癌症的恶性细胞表达趋化因子受体CXCR4，并对其配体CXCL12产生反应。这一受体配体对似乎参与癌细胞向转移部位的定向迁移、癌细胞在次优条件下存活率的提高以及肿瘤促进细胞因子/趋化因子网络的建立。动物模型的初步数据表明，CXCR4可能是多种癌症的重要治疗靶点。然而，CXCR4在胚胎发育、体内平衡和炎症中发挥着主要作用。这就引发了关于CXCR4拮抗剂在癌症治疗中特异性的问题。